Current research hotspots regarding immune checkpoint inhibitors in the treatment of endometrial cancer include microsatellite instability, mismatch repair deficiency, PD-1, PD-L1, chemotherapy, pembrolizumab, lenvatinib, and dostarlimab. This study systematically analyzes the current state of research in this field, focusing on research hotspots, emerging trends, and future development directions. Additionally, it comprehensively evaluates the most influential literature, core journals, authoritative scholars, leading research institutions, and major contributing countries in this field.

In vivo studies using Huh7 xenograft models showed that TP-LEN combination significantly suppressed tumor growth without causing hepatic or renal dysfunction, accompanied by marked downregulation of CERK, GPX4, and SLC7A11 in tumor tissues. This study confirms that TP enhances LEN sensitivity by targeting the CERK/sphingolipid-ferroptosis axis, providing a novel strategy to overcome HCC resistance.

Moreover, treatment of HepG2 cells with S-MLPs led to a 12.99-fold increase in the activity of apoptotic proteins and decreased production of angiogenic proteins from 331.57 to 83.34 pg mL-1. The R2 relaxation value of 57.262 mM-1 s-1 obtained for the MLPs, indicating their high potential for clinical cancer management.

Given the retrospective design and potential confounding of this analysis, these findings should be interpreted with caution. Anlotinib-containing regimens showed potential clinical activity in this patient population and warrant further evaluation.

Furthermore, a novel oral nanoparticle delivery system, targeting the liver tissue, enhances the therapeutic efficacy of sorafenib, restoring liver enzyme levels by up to 76%. Collectively, these findings identify middle-dose sorafenib, particularly when delivered via the novel oral nanoplatform, as an effective strategy to mitigate hepatic IRI.

P2, N=9, Completed, Daiichi Sankyo Co., Ltd. | Active, not recruiting --> Completed

P1/2, N=40, Recruiting, Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University

The combination of transarterial chemoembolization (TACE), lenvatinib and PD-1 inhibitors (triple therapy) demonstrates encouraging efficacy in patients with unresectable hepatocellular carcinoma (uHCC)...Triple therapy demonstrates promising efficacy and an acceptable safety profile in patients with double-negative DCP/AFP uHCC. The SEA score effectively stratifies patient outcomes, facilitating the identification of optimal candidates for triple therapy, though prospective validation is warranted before widespread clinical use.

The patient received external beam radiotherapy and systemic therapy with lenvatinib; however, the disease progressed, and he died 16 months after the diagnosis of cavernous sinus metastasis. This case highlights the aggressive potential of FTC, the limitations of radioiodine imaging in dedifferentiated disease, and the poor prognosis associated with skull-base metastases despite multimodal therapy.

Lisaftoclax, a small-molecule inhibitor that disrupts the DHODH-TRIM28 interaction, potentiates sunitinib efficacy and exerts a synergistic therapeutic effect. Collectively, our findings identify DHODH as a critical therapeutic target for overcoming sunitinib resistance in RCC and provide a novel strategy for the treatment of RCC.

Cellular Ki values of dasatinib and imatinib for 25 kinases by FPCBA were broadly concordant with kinobead LC/MS measurements in cancer cell lysates but diverged substantially from recombinant KINOMEscan values, with divergences attributable to competition with ATP, autoinhibition, and membrane-dependent conformational states in living cells. FPCBA enables profiling of native protein-small molecule interactions in a physiologically relevant cellular context.

Immunohistochemical analyses of pancreatic cancer tissues revealed high VEGFR2 expression in 83% (67/80) of samples, significantly exceeding the levels observed in normal pancreatic tissues. These results underscore VEGFR2 as a promising molecular target and propose a novel therapeutic avenue for KRAS-mutant cancers.